The result shows that, when the random effects model was used, the mean difference (MD) of visfatin plasma concentrations was significantly higher in breast cancer patients than in healthy subjects (MD = 9.41, 95% confidence interval (CI) = 4.51–14.31), which indicates the importance of visfatin in breast cancer patients (Figure 1). This evidence concerns the gene NAMPT and breast carcinoma.